Met Life Investment Management, LLC Inhibrx, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$32.76 - $39.56 $596,035 - $719,754	18,194 New	18,194 $636,000
Q3 2023 May 09, 2024	BUY	$15.75 - $26.31 $7,056 - $11,786	448 Added 2.52%	18,194 $333,000
Q2 2023 Apr 29, 2024	BUY	$16.96 - $27.82 $308,570 - $506,157	18,194 New	18,194 $472,000
Q2 2023 Aug 10, 2023	BUY	$16.96 - $27.82 $7,598 - $12,463	448 Added 2.52%	18,194 $472,000
Q1 2023 May 09, 2024	BUY	$18.45 - $27.14 $327,413 - $481,626	17,746 New	17,746 $335 Million
Q4 2022 May 10, 2024	BUY	$20.18 - $33.33 $10,473 - $17,298	519 Added 3.01%	17,746 $437,000
Q4 2022 Mar 22, 2023	BUY	$20.18 - $33.33 $10,473 - $17,298	519 Added 3.01%	17,746 $437,000
Q4 2022 Feb 15, 2023	BUY	$20.18 - $33.33 $10,473 - $17,298	519 Added 3.01%	17,746 $437,000
Q3 2022 Jun 14, 2023	SELL	$11.58 - $24.73 $6,010 - $12,834	-519 Reduced 2.92%	17,227 $309,000
Q2 2022 Jun 20, 2023	SELL	$8.52 - $25.26 $4,421 - $13,109	-519 Reduced 2.92%	17,227 $195,000
Q1 2022 May 10, 2024	BUY	$19.89 - $43.18 $342,645 - $743,861	17,227 New	17,227 $383,000
Q1 2022 Jun 20, 2023	SELL	$19.89 - $43.18 $10,322 - $22,410	-519 Reduced 2.92%	17,227 $383,000
Q1 2022 Mar 22, 2023	BUY	$19.89 - $43.18 $113,452 - $246,298	5,704 Added 49.5%	17,227 $383,000
Q1 2022 May 12, 2022	BUY	$19.89 - $43.18 $113,452 - $246,298	5,704 Added 49.5%	17,227 $384,000
Q4 2021 Jun 21, 2023	SELL	$26.75 - $46.02 $166,465 - $286,382	-6,223 Reduced 35.07%	11,523 $503,000
Q3 2021 Jun 21, 2023	SELL	$25.18 - $37.81 $156,695 - $235,291	-6,223 Reduced 35.07%	11,523 $383,000
Q2 2021 May 17, 2024	SELL	$14.69 - $27.52 $97,996 - $183,585	-6,671 Reduced 36.67%	11,523 $317,000
Q2 2021 Jun 21, 2023	SELL	$14.69 - $27.52 $91,415 - $171,256	-6,223 Reduced 35.07%	11,523 $317,000
Q2 2021 Mar 22, 2023	BUY	$14.69 - $27.52 $111,056 - $208,051	7,560 Added 190.76%	11,523 $317,000
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $169,272 - $317,112	11,523 New	11,523 $317,000
Q1 2021 May 14, 2021	SELL	$16.27 - $41.26 $64,478 - $163,513	-3,963 Closed	0 $0
Q4 2020 May 24, 2024	SELL	$15.96 - $50.0 $227,126 - $711,550	-14,231 Reduced 78.22%	3,963 $130,000
Q4 2020 Jun 22, 2023	SELL	$15.96 - $50.0 $219,976 - $689,150	-13,783 Reduced 77.67%	3,963 $130,000
Q4 2020 Mar 22, 2023	SELL	$15.96 - $50.0 $219,976 - $689,150	-13,783 Reduced 77.67%	3,963 $130,000
Q4 2020 Feb 16, 2021	BUY	$15.96 - $50.0 $63,249 - $198,150	3,963 New	3,963 $131,000

Others Institutions Holding INBX

# of Institutions

Shares Held

18.6K

Call Options Held

Put Options Held

Credit Suisse Ag Zurich, V8

18.6K
Shares

$286,767
0.0% of portfolio

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $603M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account